Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Discard any solution that appears cloudy or contains particles
Functional medicine focuses on discovering the root causes of health issues rather than just managing symptoms
Step 3 Treat & Repair Follow with DNA Total Repair to target signs of UV damage, pigmentation irregularities, and visible aging at the cellular level, supporting natural repair processes
Collagen and elastin production
US$ 22.54
US$ 21.74
US$ 23.95
US$ 27.01
)
US$ 24.74
